Eribulin mesylate is under clinical development by Eisai and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Eribulin mesylate’s likelihood of approval (LoA) and phase transition for Ovarian Cancer took place on 22 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Eribulin mesylate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Eribulin mesylate overview

Eribulin mesylate (E-7389, Halaven,Teceris) is a microtubule dynamics inhibitor belonging to the halichondrin class of antineoplastic agents. It is formulated as a solution for the intravenous route of administration. It is indicated for the treatment of patients with locally advanced or metastatic breast cancer and unresectable or metastatic liposarcoma (leiomyosarcoma) who have received a prior anthracycline-containing regimen. Halaven is also indicated for the treatment of patients with soft tissue sarcoma.

It is under development for the treatment of solitary firbous tumor, metastatic urothelial cell cancer, advanced metastatic breast cancer, recurrent or refractory solid tumors including lymphomas, glioblastoma, soft tissue sarcoma, relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and ewing sarcoma (EWS), triple negative breast cancer, angiosarcoma, synovial sarcoma, leiomyosarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma, liposarcoma , fibrosarcoma, clear cell sarcoma, epithelioid sarcoma, malignant peripheral nerve sheath tumor, undifferentiated sarcoma, rhabdomyosarcoma, dermatofibrosarcoma protuberance, Ewing sarcoma/primary neuroectodermal tumor, desmoplastic circle Cellular tumor, inflammatory myofibroblastic sarcoma, malignant solitary fibroma and pregressive epitheloid hemangioendothelioma (EHE). It was also under development for the treatment of HER2 positive breast cancer, HER2 negative breast cancer, metastatic hormone refractory prostate cancer, ovarian cancer, uterine cancer and non-small cell lung cancer that has progressed following two or more prior treatment regimens and bladder cancer, transitional cell cancers of the urothelium including prostate, urethra, ureter, and renal pelvis cancers.

Eisai overview

Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Quick View Eribulin mesylate LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Eribulin mesylate
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Non Malignant Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.